Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs US Bancorp — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while US Bancorp trades at $56.26 (market cap $88.64B). The key difference: US Bancorp is far larger — about 91.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and US Bancorp pays a 3.8% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and US Bancorp for 98 Days on average.
| MRVI | USB | |
|---|---|---|
Market Cap | $972.90M | $88.64B |
Volume | 4,325,710 | 8,200,583 |
Sector | Health | Financials |
52-Week High | $9.00 | $65.42 |
52-Week Low | $2.83 | $45.47 |
Typical Hold Time | 0 Days | 98 Days |
Enterprise Value | $1.08B | $118.14B |
Dividend Yield | — | 3.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
U.S. Bancorp (USB) trades at $56.89, down 0.92% with bearish technical signals but strong fundamentals including consistent earnings beats and a 27.61% net margin. The stock shows a P/E of 11.36 and ROE of 13.53%, with analyst consensus at Buy (51%) and a $69.94 price target. Recent news highlights dividend increases and strong Q3 expectations for net interest income and fee revenues.
Outlook remains positive based on valuation and earnings momentum, though risks include regulatory changes and interest rate sensitivity. The 3.8% dividend hike to $0.54 signals management confidence, but investors should monitor net cash flow trends and competitive pressures in regional banking.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
